ArticlePloS one2018

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.

Ping G Tepper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.